Our findings demonstrated that TSHR represents an exceptional tumor‐specific antigen for CAR‐T cell therapy in DTC, with high and consistent expression in primary and conventional treatment‐resistant tumors while being entirely absent in normal tissues outside the thyroid.[29, 31, 32] Critically, the surgical removal of thyroid tissue in thyroid cancer treatment uniquely eliminates the risk of on‐target/off‐tumor toxicity against healthy TSHR‐expressing cells, a major limitation plaguing CAR‐T therapy for many other solid tumors. The gene discussed is TSHR; the disease is neoplasm.